# Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine

> **NCT02546752** · EARLY_PHASE1 · COMPLETED · sponsor: **Regenstrief Institute, Inc.** · enrollment: 1306 (actual)

## Conditions studied

- Human Papilloma Virus Infection Type 11
- Human Papilloma Virus Infection Type 16
- Human Papilloma Virus Infection Type 18
- Human Papilloma Virus Infection Type 6
- Cervical Cancer

## Interventions

- **OTHER:** THEO

## Key facts

- **NCT ID:** NCT02546752
- **Lead sponsor:** Regenstrief Institute, Inc.
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 1306 (ACTUAL)
- **Last updated:** 2016-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02546752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02546752, "Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02546752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*